882 - Using of lactobacterin in combined treatment of superficial urinary bladder cancer

Date 28 September 2012
Event ESMO Congress 2012
Session Publication Only
Topics Urothelial Cancers
Presenter Sharaf Babakulov
Authors S. Babakulov1, S. Navruzov2
  • 1Urology, National Cancer Center of Uzbekistan, 100174 - Tashkent/UZ
  • 2Administration, National Cancer Center of Uzbekistan, 100174 - Tashkent/UZ

Abstract

Background

to improve combined treatment results of bladder cancer in combination with intra-bladder introduction of Lactobacterine. Materials and methods: During 2010 and 2011 years in National cancer research centre underwent a course of treatment 50 patients with superficial bladder cancer. Those patients divided in two groups. Main group 25 patients and control group 25 accordingly. All patients had morphological confirmed transitional cell carcinoma with histological differentiation G1-G2. Patients before hospitalization had bacteriological study of urine. Bacteriological analysis of urine revealed in 14 (28 %) patients presence of - E.Coli, in 16 (32 %) – S. aureus, in 12 (24%) - Ps. Aeruginosa and in 8 (16%) Klebsiella. After diagnosing of histological structure of the tumor and bladder microflora patients undergone transurethral resection of tumor. Patients in control group after TUR took intravisical chemotherapy with doxorubicin 50 mg once in a week 6 courses. Patients in main group after TUR took intravisical chemotherapy with doxorubicin 50 mg once in a week 6 courses and instillation of collibacterin. Treatment regimen was everyday instillation of probiotic collibacterin 20 mg (5 doses) dissolving in 30 ml of 5% glucose solution per day during 5 days. After the course patients took 3 mg of dried collibacterin per os during the year.

Results

It was detected that side effects of intravisical chemotherapy in the form of bladder disorders in control group was revealed almost in every case. Patients of main group only 2 of them had insignificant pain during urination. Study of one year recurrent free survival rate showed that in main group one patient had recurrence of cancer in 310 th day after surgery. In control group 8 (32%) patients had recurrence in the course of year after operation.

Conclusions

Using of intravisical probioticotherapy in combined treatment of superficial urinary bladder cancer allows to decrease side effects of chemotherapy and prolong one year recurrent free survival rate with superficial urinary bladder cancer.

Disclosure

All authors have declared no conflicts of interest.